CLOs on the Move

Accelerate Diagnostics

www.acceleratediagnostics.com

 
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The companys revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Michael Bridge
 General Counsel Profile

Similar Companies

Optident

Optident is a Springfield, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telemed Systems Inc

Telemed Systems Inc is a Hudson, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Mainstay Medical

Mainstay is a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP).

SwipeSense

SwipeSense is a healthcare technology company, our mission is to eliminate Hospital Acquired Infections, a leading cause of death in the United States. We design and market the only comprehensive hand-hygiene performance system which combines sensor networks with wearable hand hygiene dispensers to provide a complete, long-term and cost-effective hand hygiene system for healthcare institutions.

AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date.